Furthermore, administration of JAK2 inhibitors, including baricitinib and Huang Gan formula, effectively improves kidney function in CKD and DKD, which indicates that JAK2 inhibitors might be useful as new therapies for CKD and DKD38,39. This evidence concerns the gene JAK2 and chronic kidney disease.